Sepul Bio is a business unit within Thea exclusively focused on developing treatments for inherited retinal diseases. Sepul Bio’s initial focus will be to develop two flagship assets: Sepofarsen and Ultevursen.
Sepofarsen is an investigational RNA therapy targeting Leber congenital amaurosis 10. This therapy is designed to address vision problems by addressing the underlying genetic mutation. Sepofarsen aims to skip aberrant mutation in the mRNA, leading to the production of functional protein. Ultevursen, also based on RNA technology, is aimed at addressing vision loss in Usher syndrome type 2a and non-syndromic retinitis pigmentosa.